{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T19:44:37Z","timestamp":1767901477710,"version":"3.49.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"13","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T00:00:00Z","timestamp":1721174400000},"content-version":"vor","delay-in-days":77,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.vaccine.2024.03.071","type":"journal-article","created":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T13:55:06Z","timestamp":1712930106000},"page":"3180-3189","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Phase 3 immunogenicity and safety study of a tick-borne encephalitis vaccine in healthy Japanese participants 1 year of age and older"],"prefix":"10.1016","volume":"42","author":[{"given":"Motoharu","family":"Yonekawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tohru","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Kogawara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7449-3481","authenticated-orcid":false,"given":"Chihiro","family":"Yoshii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masako","family":"Yamaji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakazu","family":"Aizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilhelm","family":"Erber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuhei","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bogdan","family":"Jug","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doris","family":"Koelch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"de Solom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen P.","family":"Lockhart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2024.03.071_b0005","doi-asserted-by":"crossref","first-page":"430","DOI":"10.12998\/wjcc.v3.i5.430","article-title":"Tick-borne encephalitis: a review of epidemiology, clinical characteristics, and management","volume":"3","author":"Bogovic","year":"2015","journal-title":"World J Clin Cases"},{"key":"10.1016\/j.vaccine.2024.03.071_b0010","doi-asserted-by":"crossref","first-page":"10615","DOI":"10.3390\/ijms221910615","article-title":"Selected biomarkers of tick-borne encephalitis: a review","volume":"22","author":"Gudowska-Sawczuk","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.vaccine.2024.03.071_b0015","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.3390\/microorganisms10071283","article-title":"Recommendations to improve tick-borne encephalitis surveillance and vaccine uptake in Europe","volume":"10","author":"Kunze","year":"2022","journal-title":"Microorganisms"},{"key":"10.1016\/j.vaccine.2024.03.071_b0020","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/1756-3305-6-180","article-title":"New endemic foci of tick-borne encephalitis (TBE) identified in districts where testing for TBE was not available before 2009 in Poland","volume":"6","author":"Stefanoff","year":"2013","journal-title":"Parasit Vectors"},{"key":"10.1016\/j.vaccine.2024.03.071_b0025","unstructured":"Centers for Disease Control and Prevention. Tick-borne encephalitis (TBE). Transmission, https:\/\/www.cdc.gov\/tick-borne-encephalitis\/transmission\/index.html; 2022 [accessed June 19, 2023]."},{"key":"10.1016\/j.vaccine.2024.03.071_b0030","unstructured":"Hills S, Gould C, Cossaboom C. Tick-borne encephalitis. In: CDC Yellow Book 2024: Health Information for International Travel: Oxford University Press; 2023."},{"key":"10.1016\/j.vaccine.2024.03.071_b0035","unstructured":"European Centre for Disease Prevention and Control. Factsheet about tick-borne encephalitis (TBE), https:\/\/www.ecdc.europa.eu\/en\/tick-borne-encephalitis\/facts\/factsheet; [accessed May 8, 2023]."},{"key":"10.1016\/j.vaccine.2024.03.071_b0040","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3390\/jcm11030803","article-title":"Incidence of tick-borne encephalitis during the COVID-19 pandemic in selected European countries","volume":"11","author":"Zaj\u0105c","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.vaccine.2024.03.071_b0045","unstructured":"European Centre for Disease Prevention and Control. Tick-borne encephalitis - Annual Epidemiological Report for 2020, https:\/\/www.ecdc.europa.eu\/en\/publications-data\/tick-borne-encephalitis-annual-epidemiological-report-2020; 2022 [accessed May 18, 2023]."},{"key":"10.1016\/j.vaccine.2024.03.071_b0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2019.01.004","article-title":"Tick-borne encephalitis in Europe: a brief update on epidemiology, diagnosis, prevention, and treatment","volume":"62","author":"Riccardi","year":"2019","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.vaccine.2024.03.071_b0055","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1080\/14760584.2022.2108798","article-title":"Travelers' preferences for tick-borne encephalitis vaccination","volume":"21","author":"Poulos","year":"2022","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2024.03.071_b0060","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/S0264-410X(02)00814-9","article-title":"History of TBE vaccines","volume":"21","author":"Barrett","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.03.071_b0065","unstructured":"European Centre for Disease Prevention and Control. Tick-borne encephalitis: recommended vaccinations, https:\/\/vaccine-schedule.ecdc.europa.eu\/Scheduler\/ByDisease?SelectedDiseaseId=27&SelectedCountryIdByDisease=-1; 2023 [accessed May 8, 2023]."},{"key":"10.1016\/j.vaccine.2024.03.071_b0070","unstructured":"TICOVAC (tick-borne encephalitis vaccine). Full Prescribing Information, Pfizer Inc, New York, NY."},{"key":"10.1016\/j.vaccine.2024.03.071_b0075","doi-asserted-by":"crossref","unstructured":"Demicheli V, Debalini MG, Rivetti A. Vaccines for preventing tick-borne encephalitis. Cochrane Database Syst Rev 2009;2009:Cd000977. Doi: 10.1002\/14651858.CD000977.pub2.","DOI":"10.1002\/14651858.CD000977.pub2"},{"key":"10.1016\/j.vaccine.2024.03.071_b0080","first-page":"241","article-title":"Vaccines against tick-borne encephalitis: WHO position paper","volume":"86","author":"World Health Organization","year":"2011","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2024.03.071_b0085","unstructured":"Pfizer Inc. U.S. FDA approves TICOVAC\u2122, Pfizer\u2019s tick-borne encephalitis (TBE) vaccine, https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/us-fda-approves-ticovactm-pfizers-tick-borne-encephalitis; 2021 [accessed May 8, 2023]."},{"key":"10.1016\/j.vaccine.2024.03.071_b0090","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/j.vaccine.2008.10.003","article-title":"Antibody response following administration of two paediatric tick-borne encephalitis vaccines using two different vaccination schedules","volume":"27","author":"Wittermann","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.03.071_b0095","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1038\/emi.2017.69","article-title":"Tick-borne encephalitis in Japan, Republic of Korea and China","volume":"6","author":"Yoshii","year":"2017","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.vaccine.2024.03.071_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ttbdis.2022.101900","article-title":"Characterization of tick-borne encephalitis virus isolated from tick infesting dog in Central Hokkaido in 2018","volume":"13","author":"Takahashi","year":"2022","journal-title":"Ticks Tick Borne Dis"},{"key":"10.1016\/j.vaccine.2024.03.071_b0105","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.3390\/microorganisms8111672","article-title":"A retrospective epidemiological study of tick-borne encephalitis virus in patients with neurological disorders in Hokkaido, Japan.","volume":"8","author":"Yoshii","year":"2020","journal-title":"Microorganisms"},{"key":"10.1016\/j.vaccine.2024.03.071_b0110","first-page":"128","article-title":"Evaluation of testing methods and retrospective survey results for tick-borne encephalitis","volume":"44","author":"Yamaguchi","year":"2023","journal-title":"IASR"},{"key":"10.1016\/j.vaccine.2024.03.071_b0115","unstructured":"Ando K, Kuratsuka K, Arima S, Hironaka N, Honda Y, Ishii K. Studies on the viruses isolated during epidemic of Japanese B encephalitis in 1948 in Tokyo area. Kitasato Arch Exp Med 1952;24:557-62; English transl 429-41."},{"key":"10.1016\/j.vaccine.2024.03.071_b0120","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/S0264-410X(98)00360-0","article-title":"Protection against tick-borne encephalitis virus isolated in Japan by active and passive immunization","volume":"17","author":"Chiba","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.03.071_b0125","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1128\/jcm.35.8.1943-1947.1997","article-title":"A case of tick-borne encephalitis in Japan and isolation of the the virus","volume":"35","author":"Takashima","year":"1997","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2024.03.071_b0130","doi-asserted-by":"crossref","first-page":"2278898","DOI":"10.1080\/22221751.2023.2278898","article-title":"First evidence of tick-borne encephalitis (TBE) outside of Hokkaido Island in Japan","volume":"12","author":"Ohira","year":"2023","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.vaccine.2024.03.071_b0135","unstructured":"Pharma Japan. Pfizer files tick-borne encephalitis vaccine in Japan. https:\/\/pj.jiho.jp\/article\/248576; 2023 [accessed May 8, 2023]."},{"key":"10.1016\/j.vaccine.2024.03.071_b0140","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1093\/infdis\/jir122","article-title":"A tick-borne encephalitis virus vaccine based on the European prototype strain induces broadly reactive cross-neutralizing antibodies in humans","volume":"203","author":"Orlinger","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2024.03.071_b0145","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/(SICI)1096-9071(199601)48:1<102::AID-JMV16>3.0.CO;2-I","article-title":"Correlation between ELISA, hemagglutination inhibition, and neutralization tests after vaccination against tick-borne encephalitis","volume":"48","author":"Holzmann","year":"1996","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2024.03.071_b0150","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1080\/00365540110027358","article-title":"Pharmacokinetics of human tick-borne encephalitis virus antibody levels after injection with human tick-borne encephalitis immunoglobulin, solvent\/detergent treated, FSME-BULIN S\/D in healthy volunteers","volume":"33","author":"Adner","year":"2001","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.vaccine.2024.03.071_b0155","unstructured":"World Health Organization. Japanese encephalitis. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/japanese-encephalitis; 2019 [accessed February 2, 2024]."},{"key":"10.1016\/j.vaccine.2024.03.071_b0160","unstructured":"World Health Organization. Vaccination schedule for Japan. https:\/\/immunizationdata.who.int\/pages\/schedule-by-country\/jpn.html; 2024 [accessed February 2, 2024]."},{"key":"10.1016\/j.vaccine.2024.03.071_b0165","doi-asserted-by":"crossref","first-page":"5256","DOI":"10.1016\/j.vaccine.2006.03.061","article-title":"Safety and immunogenicity of the modified adult tick-borne encephalitis vaccine FSME-IMMUN: results of two large phase 3 clinical studies","volume":"24","author":"Loew-Baselli","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.03.071_b0170","doi-asserted-by":"crossref","first-page":"7307","DOI":"10.1016\/j.vaccine.2011.07.089","article-title":"Prevention of tick-borne encephalitis by FSME-IMMUN vaccines: review of a clinical development programme","volume":"29","author":"Loew-Baselli","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.03.071_b0175","doi-asserted-by":"crossref","first-page":"4558","DOI":"10.1016\/j.vaccine.2010.04.075","article-title":"Clinical evaluation to determine the appropriate paediatric formulation of a tick-borne encephalitis vaccine","volume":"28","author":"P\u00f6llabauer","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.03.071_b0180","doi-asserted-by":"crossref","first-page":"4680","DOI":"10.1016\/j.vaccine.2010.04.047","article-title":"Comparison of immunogenicity and safety between two paediatric TBE vaccines","volume":"28","author":"P\u00f6llabauer","year":"2010","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24003888?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24003888?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T19:35:59Z","timestamp":1760816159000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24003888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":36,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S0264410X24003888"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.03.071","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 3 immunogenicity and safety study of a tick-borne encephalitis vaccine in healthy Japanese participants 1 year of age and older","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.03.071","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Pfizer R&D Japan. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}